A Phase 3b/4 Randomized, Open-label, Efficacy Assessor-Blinded Study, to Evaluate the Efficacy and Safety of Upadacitinib for the Treatment of Adult Subjects with Moderate to Severe Atopic Dermatitis and Inadequate Response to Dupilumab (SWITCH-UP)

Status

Not yet recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523347-35-00

Enrollment

Registered

2026-02-02

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Brief summary

Participants who achieve at least a 90% reduction in Eczema Area and Severity Index from Baseline (EASI 90) at Week 8

Detailed description

Percentage of participants who achieve a Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 8, Participants who simultaneous achieve at least a 90% reduction in Eczema Area and Severity Index from Baseline (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 8, Percentage of participants achieving worst pruritus numerical rating scale (WP-NRS) 0/1 at Week 4

Interventions

DRUGUpadacitinib

DRUGDUPILUMAB

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Participants who achieve at least a 90% reduction in Eczema Area and Severity Index from Baseline (EASI 90) at Week 8	—

Secondary

Measure	Time frame
Percentage of participants who achieve a Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 8, Participants who simultaneous achieve at least a 90% reduction in Eczema Area and Severity Index from Baseline (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 8, Percentage of participants achieving worst pruritus numerical rating scale (WP-NRS) 0/1 at Week 4	—

Measure

Time frame

—

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026